These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 38102305)
1. Feasibility of robotic platform to perform R0 resection for locally advanced multi-visceral pelvic malignancy: an institutional experience on outcomes of robotic pelvic exenteration. Saqib SU; Raza MZ; Twigg J; Altan O; Bajwa AA Langenbecks Arch Surg; 2023 Dec; 409(1):9. PubMed ID: 38102305 [TBL] [Abstract][Full Text] [Related]
2. Robotic pelvic exenteration and extended pelvic resections for locally advanced or synchronous rectal and urological malignancy. Williams M; Perera M; Nouhaud FX; Coughlin G Investig Clin Urol; 2021 Jan; 62(1):111-120. PubMed ID: 33381928 [TBL] [Abstract][Full Text] [Related]
3. Robotic multivisceral pelvic resection: experience from an exenteration unit. Smith N; Murphy DG; Lawrentschuk N; McCormick J; Heriot A; Warrier S; Lynch AC Tech Coloproctol; 2020 Nov; 24(11):1145-1153. PubMed ID: 32662050 [TBL] [Abstract][Full Text] [Related]
4. Minimally Invasive Surgery for Pelvic Exenteration in Primary Colorectal Cancer. Kumar NA; Sasi SP; Shinde RS; Verma K; Sugoor P; Desouza A; Engineer R; Saklani A JSLS; 2020; 24(3):. PubMed ID: 32714002 [TBL] [Abstract][Full Text] [Related]
5. Robotic beyond total mesorectal excision surgery for primary and recurrent pelvic malignancy: Feasibility and short-term outcomes. Larach JT; Flynn J; Fernando D; Mohan H; Rajkomar A; Waters PS; Kong J; McCormick JJ; Heriot AG; Warrier SK Colorectal Dis; 2022 Jul; 24(7):821-827. PubMed ID: 35373888 [TBL] [Abstract][Full Text] [Related]
6. Feasibility of laparoscopic-assisted transanal pelvic exenteration in locally advanced rectal cancer with anterior invasion. Nonaka T; Tominaga T; Akazawa Y; Sawai T; Nagayasu T Tech Coloproctol; 2021 Jan; 25(1):69-74. PubMed ID: 32815047 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of transanal minimally invasive surgery for total pelvic exenteration for advanced primary and recurrent pelvic malignancies. Beppu N; Ito K; Otani M; Imada A; Matsubara T; Song J; Kimura K; Kataoka K; Kuwahara R; Horio Y; Uchino M; Ikeuchi H; Ikeda M Tech Coloproctol; 2023 Dec; 27(12):1367-1375. PubMed ID: 37878167 [TBL] [Abstract][Full Text] [Related]
8. Survival and morbidity outcomes after pelvic exenteration for pelvic sarcoma: an institutional series. Lee PJ; Meshkat B; Sasidharan P; Zahid A; Coker DJ; Solomon MJ ANZ J Surg; 2022 May; 92(5):1038-1043. PubMed ID: 34661958 [TBL] [Abstract][Full Text] [Related]
10. Cystoprostatectomy versus prostatectomy alone for locally advanced or recurrent pelvic cancer. Turner GA; Harris CA; Eglinton TW; Wakeman CJ; Kueppers F; Dixon L; Dobbs BR; Frizelle FA ANZ J Surg; 2016; 86(1-2):54-8. PubMed ID: 25113257 [TBL] [Abstract][Full Text] [Related]
11. Total pelvic exenteration for primary and recurrent malignancies. Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of transperineal minimal invasive surgery when performing sacrectomy for advanced primary and recurrent pelvic malignancies. Beppu N; Ito K; Otani M; Imada A; Matsubara T; Song J; Kimura K; Kataoka K; Kuwahara R; Horio Y; Uchino M; Ikeuchi H; Ikeda M Tech Coloproctol; 2024 Jul; 28(1):80. PubMed ID: 38971941 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study of using basement membrane biological products in pelvic floor reconstruction during pelvic exenteration]. Chen GL; Wang YL; Zhang X; Tao Y; Sun YH; Chen JN; Wang SQ; Su N; Wang ZG; Zhang J Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Mar; 26(3):268-276. PubMed ID: 36925127 [No Abstract] [Full Text] [Related]
14. Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature. Bizzarri N; Chiantera V; Ercoli A; Fagotti A; Tortorella L; Conte C; Cappuccio S; Di Donna MC; Gallotta V; Scambia G; Vizzielli G J Minim Invasive Gynecol; 2019; 26(7):1316-1326. PubMed ID: 30611973 [TBL] [Abstract][Full Text] [Related]
15. Application of minimally invasive approaches to pelvic exenteration for locally advanced and locally recurrent pelvic malignancy - A narrative review of outcomes in an evolving field. Casey L; Larach JT; Waters PS; Kong JC; McCormick JJ; Heriot AG; Warrier SK Eur J Surg Oncol; 2022 Nov; 48(11):2330-2337. PubMed ID: 36068124 [TBL] [Abstract][Full Text] [Related]
16. Minimally invasive pelvic exenteration for gynaecological malignancy: A single-centre case series and review of the literature. Karkia R; Tailor A; Ellis P; Madhuri T; Scala A; Read J; Perry M; Patil K; Blackburn A; Butler-Manuel S; Chatterjee J Eur J Obstet Gynecol Reprod Biol; 2022 Jul; 274():56-61. PubMed ID: 35584578 [TBL] [Abstract][Full Text] [Related]
18. [Observational study on perioperative outcomes of pelvic exenteration]. Yuan H; Yao B; Li JT; Zhu WL; Ren DL; Wang H; Ma TH; Chen SQ; Wu JJ; Tao YR; Ye L; Wang ZY; Qu H; Ma B; Zhong WW; Wang DJ; Qiu JG Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Mar; 26(3):260-267. PubMed ID: 36925126 [No Abstract] [Full Text] [Related]
19. Minimally invasive versus open pelvic exenterations for rectal cancer: a comparative analysis of perioperative and 3-year oncological outcomes. Kazi M; Kumar NAN; Rohila J; Sukumar V; Engineer R; Ankathi S; Desouza A; Saklani A BJS Open; 2021 Sep; 5(5):. PubMed ID: 34518872 [TBL] [Abstract][Full Text] [Related]